Related Experiment Videos
Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing
S Bailey1, B Bolognese, D R Buckle
1SmithKline Beecham Pharmaceuticals, Epsom, Surrey, UK.
Bioorganic & Medicinal Chemistry Letters
|January 1, 1999
Summary
New hydroxamic acids inhibit the breakdown of the low affinity IgE receptor. These compounds, related to Batimastat, show distinct structural requirements for inhibition compared to collagenase inhibitors.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Immunology
Background:
- Matrix metalloproteinases (MMPs) play roles in various physiological and pathological processes.
- The low affinity IgE receptor (FcεRII/CD23) is involved in allergic responses and B cell regulation.
- Batimastat is a known non-selective MMP inhibitor.
Purpose of the Study:
- To synthesize and evaluate a series of hydroxamic acids as inhibitors of FcεRII/CD23 cleavage.
- To investigate the structure-activity relationships (SAR) for inhibition of FcεRII/CD23 proteolysis.
- To compare the SAR of FcεRII/CD23 inhibition with that of collagenase inhibition.
Main Methods:
- Synthesis of novel hydroxamic acid derivatives.
- Inhibition assays using cell membrane preparations to measure proteolytic cleavage of FcεRII/CD23.
- Structure-activity relationship analysis.
Main Results:
- Several synthesized hydroxamic acids effectively inhibited the proteolytic cleavage of FcεRII/CD23.
- The SAR studies indicated that the structural requirements for inhibiting FcεRII/CD23 cleavage are different from those for inhibiting collagenase.
- This suggests potential for developing selective inhibitors.
Conclusions:
- Hydroxamic acids can be designed to inhibit the cleavage of the low affinity IgE receptor.
- The distinct SAR highlights opportunities for developing selective MMP inhibitors targeting FcεRII/CD23.
- These findings could inform the development of new therapeutics for IgE-mediated allergic diseases.